头孢他啶药物利用评价标准的建立与应用

Formulation and Application of Drug Use Evaluation Criteria for Ceftazidime

目的建立头孢他啶药物利用评价(DUE)标准,为临床合理使用头孢他啶提供依据。方法以注射用头孢他啶(凯复定)药品说明书为基础,参考相关书籍及指南,结合医院实际情况制订头孢他啶DUE标准。采用随机抽样法抽取医院2022年1月至2023年12月使用头孢他啶抗感染治疗的出院病历,参照DUE标准对患者的用药指征、用药过程、用药结果、管理指标等项目进行合理性评价。结果共纳入病历192份,涉及患者192例,男103例(53.65%)、女89例(46.35%),年龄10~102岁,平均住院(10.55±5.66)d,集中于急诊内科(55例、28.65%)、肺病科(49例、25.52%)、普通外科(30例、15.62%)等。与DUE标准符合的用药指征包括适应证、禁忌证,符合率分别为98.44%,100%;用药过程包括生命体征及实验室指标、用法、用量、溶剂、特殊人群、用药疗程、联合用药、药物相互作用,符合率分别为66.15%,100%,82.81%,100%,78.29%,73.44%,98.21%,97.40%;用药结果包括治疗效果、不良反应,符合率分别为92.19%,94.79%;管理指标包括处方权和病程记录,符合率分别为100%,96.35%。结论本研究中所建立的DUE标准,可用于监测和分析头孢他啶的临床使用情况,有利于发现用药问题,规范医师合理用药。

Objective To formulate a drug use evaluation(DUE)criteria for ceftazidime,and to provide a basis for its rational use in clinical practice.Methods Based on the instruction of Ceftazidime for Injection(Kefadim),relevant books and guidelines,the DUE criteria for ceftazidime were formulated according to the actual status of the hospital.The medical records of patients using ceftazidime for anti-infection discharged from the hospital from January 2022 to December 2023 were selected by the random sampling method.The rationality of patients′medication signs,medication process,medication outcomes and management indicators were evaluated based on the DUE criteria.Results A total of 192 medical records were included,involving 192 patients,including 103 males(53.65%)and 89 females(46.35%),aged 10-102 years,with an average hospital stay of(10.55±5.66)d.The patients mainly were in the Department of Emergency Internal Medicine(55 cases,28.65%),Department of Pulmonary Diseases(49 cases,25.52%),Department of General Surgery(30 cases,15.62%),etc.The medication signs that met the DUE criteria included indications and contraindications,with the coincidence rates of 98.44%,100%respectively.The medication processes that met the DUE criteria included vital signs and laboratory indicators,usage,dosage,solvents,special populations,medication duration,combined medication and drug-drug interactions,with coincidence rates of 66.15%,100%,82.81%,100%,78.29%,73.44%,98.21%,97.40%respectively.The medication outcomes that met the DUE criteria included treatment efficacy and adverse reactions,with coincidence rates of 92.19%,94.79%respectively.The management indicators that met the DUE criteria included prescription rights and progress note,with coincidence rates of 100%,96.35%respectively.Conclusion The formulated DUE criteria in this study can be used to monitor and analyze the clinical use of ceftazidime,which is beneficial for identifying medication problems and promoting rational drug use by physicians.